MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-15-2026
ENDRA Life Sciences Retained Earnings 2011-2026 | NDRA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -110 M | -103 M | -91.9 M | -81.9 M | -68.7 M | -57.3 M | -45.2 M | -27.7 M | -17.9 M | -12.5 M | -9.74 M | -7.46 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.46 M | -110 M | -52.9 M |
Quarterly Retained Earnings ENDRA Life Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -112 M | -107 M | -106 M | -104 M | -103 M | - | -96.9 M | -94.7 M | -91.9 M | -90.5 M | -87.4 M | -84.8 M | -81.9 M | -78.6 M | -75.1 M | -71.5 M | -68.7 M | -65.6 M | -62.9 M | -59.7 M | -57.3 M | -55.1 M | -57.3 M | -57.3 M | -45.2 M | -45.2 M | -45.2 M | -45.2 M | -27.7 M | -27.7 M | -27.7 M | -27.7 M | -17.9 M | -17.9 M | -17.9 M | -17.9 M | -12.5 M | -12.5 M | -12.5 M | -12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -12.5 M | -112 M | -58.5 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B |  USA |
 |
Agilent Technologies
A
|
348 M | $ 115.08 | 0.1 % | $ 35 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 134.26 | -2.87 % | $ 6.28 B | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 9.11 | 79.68 % | $ 12.1 M | USA |
 |
Castle Biosciences
CSTL
|
-224 M | $ 19.69 | -2.28 % | $ 571 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-719 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
530 M | $ 17.67 | 3.27 % | $ 544 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
-735 M | $ 21.54 | -0.42 % | $ 1.15 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 119.85 | 0.76 % | $ 15 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-166 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.8 | -1.1 % | $ 7.96 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 113.85 | -2.51 % | $ 9.39 B |  Irlanda |
 |
Illumina
ILMN
|
-1.24 B | $ 145.23 | 0.56 % | $ 23.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-166 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
680 M | $ 100.06 | -2.85 % | $ 6.75 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 156.73 | -2.23 % | $ 7.77 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 101.33 | -0.16 % | $ 22.7 B |  Schweiz |
 |
Medpace Holdings
MEDP
|
-460 M | $ 429.11 | -0.85 % | $ 12.4 B | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 9.27 | 0.43 % | $ 1.19 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 19.04 | -0.21 % | $ 426 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Natera
NTRA
|
-1.94 B | $ 200.91 | -1.12 % | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 3.85 | 0.79 % | $ 357 M | USA |
 |
Personalis
PSNL
|
-631 M | $ 8.94 | 5.55 % | $ 798 M | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 6.43 | 1.42 % | $ 268 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Soleno Therapeutics
SLNO
|
-431 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.47 | -0.8 % | $ 5.67 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 258.45 | -0.57 % | $ 21.5 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 64.87 | 7.1 % | $ 3.88 B | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 448.18 | -0.02 % | $ 169 B | USA |
 |
Waters Corporation
WAT
|
10.4 B | $ 338.64 | -1.09 % | $ 20.2 B | USA |
 |
Trinity Biotech plc
TRIB
|
-79.1 M | $ 0.65 | 7.49 % | $ 233 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.14 | 2.7 % | $ 1.98 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 192.88 | -1.19 % | $ 21.4 B | USA |